Knowledge center

The place to find all the most innovative research and information on novel biologics and biosimilars.

Press Releases

Polpharma Biologics’ investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®*

Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars, today announced topline results demonstrating the pharmacokinetic (PK) and pharmacodynamics (PD) comparability of its biosimilar candidate PB016 to its reference drug, Entyvio®* (vedolizumab).


You can find all the latest presentations, brochures and fact sheets below covering our solutions and portfolio.

Let’s collaborate and deliver quality biosimilars together.

Get in touch for more information.